Universal RSV Immunization: Why Consistent Policy Matters for Every Canadian

Respiratory syncytial virus (RSV) has become one of Canada’s most significant seasonal respiratory health challenges. While remarkable advances in RSV prevention now offer protection for infants, pregnant women, and older adults, experts continue to emphasize that medical innovation alone is not enough. Effective public health outcomes depend on policies that ensure these protections are available consistently across the country. A recent article published by the Canadian Healthcare Network, “Universal RSV Immunization: Policy Must Be Fit for Purpose,” highlights the growing need for a more coordinated national approach to RSV prevention. The article features insights from Dr. Vivien Brown, Lucie Marisa Bucci, Director at Bucci-Hepworth Health Services Inc., and Craig Thompson, RN, Chair and healthcare policy leader, who discuss both the progress that has been made and the work that remains.

RSV Continues to Place a Significant Burden on Canada’s Healthcare System

RSV is one of the leading causes of respiratory illness in young children, with most children experiencing an infection before the age of two. While many cases are mild, RSV can lead to serious complications including bronchiolitis, pneumonia, hospitalization, and intensive care admission. Recent Canadian research cited in the article estimates that RSV-related hospitalizations cost Canada’s healthcare system approximately $66 million annually, with infants younger than six months accounting for nearly half of those costs. Although premature infants and children with underlying medical conditions remain at elevated risk, emerging surveillance data shows that more than 80% of children hospitalized with RSV had no known risk factors, reinforcing the importance of broad prevention strategies rather than narrowly targeted programs.

New Prevention Tools Are Changing the Landscape

The availability of new RSV prevention options has transformed how healthcare providers can protect vulnerable populations. These include:

• Long-acting monoclonal antibody protection for infants (nirsevimab)
• Maternal RSV vaccination during pregnancy
• RSV vaccines for older adults

Real-world evidence continues to demonstrate impressive results. During Quebec’s first universal infant immunization program, RSV-related hospitalizations among infants were reduced by approximately 66%, while protection against emergency department visits and intensive care admissions reached as high as 86% and 88%, respectively. Ontario’s recent rollout also demonstrated strong adoption, with nearly three-quarters of newborns receiving RSV protection through infant immunization or maternal vaccination programs. These findings reinforce that effective prevention programs can significantly reduce severe illness while easing pressure on hospitals during respiratory virus season.

The Challenge Isn’t the Science—It’s Consistent Implementation

Despite these encouraging outcomes, access to RSV prevention remains inconsistent across Canada. As highlighted by Bucci, Thompson, and Dr. Brown, provincial differences in eligibility, rollout timelines, product availability, and healthcare delivery create unnecessary complexity for both families and providers. Today, an infant’s access to RSV protection may depend on factors such as:

• Province or territory of residence
• Birth timing relative to RSV season
• Hospital screening practices
• Availability of community follow-up after discharge

These inconsistencies can result in missed opportunities for immunization during the critical newborn period. The authors also point to the need for stronger national surveillance systems capable of tracking maternal vaccination status, changing RSV activity, and evolving evidence that can inform future public health decisions.

A Coordinated National Strategy Benefits Everyone

The article argues that truly universal RSV prevention requires more than new medical products—it requires coordinated public health policy. A stronger national approach would include:

• More consistent provincial and territorial immunization programs
• Better hospital screening and discharge planning
• Improved community access for infants born outside traditional RSV season
• Greater education for healthcare professionals and caregivers
• Enhanced surveillance to guide future policy decisions

Ultimately, equitable access to RSV prevention should not depend on geography or timing.

Supporting Evidence-Based Public Health Leadership

At the Meningitis Research Foundation of Canada, we recognize the importance of evidence-based public health policy that improves equitable access to preventive healthcare. We are proud to see our Director, Lucie Marisa Bucci, and Chair, Craig Thompson, contributing their expertise alongside Dr. Vivien Brown in this important national conversation. Their work highlights the value of collaboration between clinicians, researchers, and public health leaders to ensure policy evolves alongside scientific innovation. As Canada continues strengthening its respiratory disease prevention strategies, coordinated RSV immunization policies represent an important opportunity to improve health outcomes, reduce healthcare system pressures, and ensure every Canadian has access to effective protection. Read the full Canadian Healthcare Network article here: https://canadianhealthcarenetwork.ca/universal-rsv-immunization-policy-must-be-fit-purpose